EUVIMEDEUVIMED entdecken
Multizentrische Studie

Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study

Alessandra Iurlo iD, Daniele Cattaneo iD, Carmen Fava, Fausto Castagnetti, Massimiliano Bonifacio iD, Mariella D'Adda, Maria Cristina Miggiano, Isabella Capodanno, Chiara Elena, Luciano Levato, Anna Rita Scortechini, Francesca Lunghi und 22 weitere

Cancer · 2026

DOI: 10.1002/cncr.70261 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2026. Verfasst von Alessandra Iurlo und 33 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Protein Kinase Inhibitors, Neoplasm Recurrence, Local. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Approximately half of patients with chronic myeloid leukemia (CML) who attempted tyrosine kinase inhibitor (TKI) discontinuation for the first time experienced molecular relapse and restarted TKIs. Although several studies have already investigated first treatment‐free remission (TFR) attempts (TFR1), few previously published articles have focused on the plausibility and predictors of second TFR (TFR2).

Methods

To evaluate the feasibility and likelihood of TFR2 success in real‐life, 90 patients with CML regularly followed in 23 Italian hematological centers were analyzed; these patients reattempted TKI discontinuation after a first failed attempt.

Results

Forty‐five (50.0%) patients lost major molecular response after a median of 4.0 months off therapy, whereas 45 (50.0%) remained treatment‐free for a median of 18.8 months. In univariate analysis, there was no association between TFR2 and the following variables: age, gender, Sokal risk score, BCR::ABL1 transcript type, prior interferon exposure, type and number of previous TKIs, resistance to any prior TKIs, and TKI switching after TFR1. In contrast, factors identified as associated with TFR2 success included a lower ELTS risk score, a longer time from TFR1 to molecular relapse (≥3 months), as well as a longer TKI treatment and deep molecular response (DMR) duration (≥4 years) before TFR2.

Conclusions

While confirming the critical prognostic role of ELTS risk and TKI treatment and DMR duration even before TFR2, this real‐life study provides further information to support the safety of a second effort to discontinue TKIs in patients with CML, as a failed first attempt does not appear to preclude a second successful one.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myelogenous, Chronic, BCR-ABL PositiveProtein Kinase InhibitorsNeoplasm Recurrence, LocalHumansMaleFemaleMiddle AgedAgedAdultItalyFusion Proteins, bcr-ablRemission InductionAged, 80 and overRecurrenceWithholding TreatmentYoung Adult

Stichwörter der Autor:innen

chronic myeloid leukemiasecond treatment‐free remissiontyrosine kinase inhibitors

Substanzen

Protein Kinase InhibitorsFusion Proteins, bcr-abl

Autor:innen und Institutionen

  • Hematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
  • Department of Oncology and Hemato-Oncology, University of Milan, Milano, Italy.
  • Department of Clinical and Biological Sciences, University of Turin, Mauriziano Hospital, Torino, Italy.
  • Institute of Hematology "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.

ORCID-Profile: Alessandra Iurlo, Daniele Cattaneo, Massimiliano Bonifacio, Mario Tiribelli, Massimo Breccia

Zitieren

APA

Iurlo, A., Cattaneo, D., Fava, C., Castagnetti, F., Bonifacio, M., D'Adda, M., Miggiano, M. C., Capodanno, I., Elena, C., Levato, L., Scortechini, A. R., Lunghi, F., Caramella, M., Orofino, N., Maffioli, M., Bellani, V., Bonuomo, V., Grano, S., Cotilli, G., …, & Rosti, G. (2026). Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study. Cancer. https://doi.org/10.1002/cncr.70261

Vancouver

Iurlo A, Cattaneo D, Fava C, Castagnetti F, Bonifacio M, D'Adda M, et al. Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study. Cancer. 2026. doi:10.1002/cncr.70261

BibTeX
@article{Iurlo2026,
  author = {Iurlo, Alessandra and Cattaneo, Daniele and Fava, Carmen and Castagnetti, Fausto and Bonifacio, Massimiliano and D'Adda, Mariella and Miggiano, Maria Cristina and Capodanno, Isabella and Elena, Chiara and Levato, Luciano and Scortechini, Anna Rita and Lunghi, Francesca and Caramella, Marianna and Orofino, Nicola and Maffioli, Margherita and Bellani, Valentina and Bonuomo, Valentina and Grano, Selene and Cotilli, Giulia and Scalzulli, Emilia and Dalmazzo, Matteo and Crescenzi, Sabrina Leonetti and Luciano, Luigiana and Martino, Bruno and Intermesoli, Tamara and Rapezzi, Davide and Binotto, Gianni and Tiribelli, Mario and Consonni, Dario and Pane, Fabrizio and Saglio, Giuseppe and Gambacorti-Passerini, Carlo and Breccia, Massimo and Rosti, Gianantonio},
  title = {Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real‐life Italian multicenter study},
  journal = {Cancer},
  year = {2026},
  doi = {10.1002/cncr.70261}
}
Kostenlos starten →